Intimation for the Unaudited Financial Results for the Quarter ended as on June 30, 2025.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India reported Q1 FY26 revenue from operations of ₹875.5 million, down about 5% from ₹922.9 million in the same quarter last year. Despite the revenue dip, profit after tax grew to ₹276.2 million from ₹257.4 million a year ago, a rise of roughly 7%. Total expenses fell sharply to ₹609.4 million from ₹690.2 million, which is what lifted profitability. Profit before tax stood at ₹372.2 million versus ₹336.8 million last year. Earnings per share for the quarter came in at ₹11.19 compared with ₹10.42 in Q1 FY25. The statutory auditors B S R & Co. LLP issued a clean limited review report with no qualifications.
For shareholders, the picture is mixed: top-line softness year-on-year is a concern, but better cost management has lifted earnings and margins, supporting EPS growth. The stock may react modestly positive on the profit beat, though the revenue decline could cap upside.